Clinical trials for Chronic myeloid leukemia (CML)

23 currently recruiting clinical trials
Phase 3 Chronic myeloid leukemia (CML) #NCT06423911
Partie A (Non-T315I)
Chronic phase 2 3 or more ATP pocket inhibitor Allosteric inhibitor
T315I Systemic Treatment-Naive
1 recruiting site
Ascentage Pharma Group Inc.
Phase 3 Chronic myeloid leukemia (CML) #NCT06423911
Partie B (Mutation T315I)
Chronic phase T315I
1 recruiting site
Ascentage Pharma Group Inc.
Phase 2 Chronic myeloid leukemia (CML) #NCT06514534 #2024-516049-38-00
Chronic phase Accelerated phase T315I 1 2 3 or more ATP pocket inhibitor
Systemic Treatment-Naive Allosteric inhibitor
7 recruiting sites
Novartis
Phase 1 / Phase 2 Chronic myeloid leukemia (CML) #NCT04835584
LMC en phase accélérée (Phase 2 Bras C)
Accelerated phase BCR-ABL Ph+ (Philadelphia chromosome positive) 1 2 3 or more ATP pocket inhibitor Allosteric inhibitor
T315I TP53 Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2 Chronic myeloid leukemia (CML) #NCT04835584
LMC Phase Chronique (phase 1b et phase 2 Bras A et B)
Chronic phase BCR-ABL Ph+ (Philadelphia chromosome positive) 1 2 3 or more ATP pocket inhibitor Allosteric inhibitor
T315I TP53 Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2 Chronic myeloid leukemia (CML) #NCT06163430 #2023-507677-18-00
Chronic phase BCR-ABL 1 2 3 or more ATP pocket inhibitor Allosteric inhibitor
Systemic Treatment-Naive
6 recruiting sites
Terns, Inc.
Phase 1 Chronic myeloid leukemia (CML) #NCT05304377 #2023-503335-18-00
Chronic phase BCR-ABL 1 2 3 or more ATP pocket inhibitor Allosteric inhibitor
Systemic Treatment-Naive
5 recruiting sites
Enliven Therapeutics